Repligen Corp. Stock
Repligen Corp. Stock
A loss of -1.220% shows a downward development for Repligen Corp..
We see a rather positive sentiment for Repligen Corp. with 19 Buy predictions and 1 Sell predictions.
As a result the target price of 151 € shows a very positive potential of 51.82% compared to the current price of 99.46 € for Repligen Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Repligen Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Repligen Corp. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | -1.220% | -2.538% | 0.668% | -8.205% | -29.386% | -33.159% | -42.839% |
| Opko Health Inc. | 0.520% | 3.400% | -1.262% | -18.760% | -11.025% | -27.817% | -71.140% |
| Amicus Therapeutics Inc. | 0.580% | -1.066% | -2.661% | 109.913% | 0.583% | 21.307% | 58.816% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | -1.110% | -3.209% | -12.136% | -3.209% | -7.653% | -38.851% | -9.500% |
Comments
Repligen (RGEN) had its price target raised by HC Wainwright from $180.00 to $208.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target lowered by UBS Group AG from $200.00 to $195.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target lowered by Barclays PLC from $200.00 to $175.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat